Abstracts tagged "ANCA"

Abstract Number: 870 • 2015 ACR/ARHP Annual Meeting
Development of an Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patient-Reported Outcome Measure: Identification of Salient Themes and Candidate Questionnaire Item Development
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Carol McAlear⁸, Nataliya Milman⁹, Jacqueline Peck¹⁰, Judy A. Shea¹¹, Gunnar Tomasson¹², Raashid Luqmani¹³, Peter F. Cronholm⁴ and Peter A. Merkel⁸, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²NONE, Banbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹⁰NONE, Oxford, United Kingdom, ¹¹Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹²Rheumatology Section, Boston University, Boston, MA, ¹³Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs), including granulomatosis with polyangiitis (Wegener's, (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA), and microscopic polyangiitis (MPA),…
Abstract Number: 871 • 2015 ACR/ARHP Annual Meeting
Clinicians’ Perspective on Aspects of ANCA-Associated Vasculitis That Influence Patients’ Function and General Health: A Delphi Exercise Based on the International Classification of Function, Disability and Health
Nataliya Milman¹, Peter Tugwell², Annelies Boonen³ and Peter A. Merkel⁴, ¹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ²Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a multisystem condition that results in significant level of morbidity and functional limitations for many patients. Previous studies showed that…
Abstract Number: 873 • 2015 ACR/ARHP Annual Meeting
The ANCA-Vasculitis Index of Damage (AVID): Performance of a New Damage Instrument
Eli Miloslavsky^1,2, Na Lu³, Sebastian Unizony³, Hyon K. Choi³, Peter A. Merkel⁴, Philip Seo⁵, Robert F. Spiera⁶, Carol A. Langford⁷, Gary S. Hoffman⁷, Cees Kallenberg⁸, E. William St.Clair⁹, Nadia Tchao¹⁰, Fernando Fervenza¹¹, Paul A. Monach¹², Ulrich Specks¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology/Clin Immunol AA21, Univer Med Center Groningen, Groningen, Netherlands, ⁹Rheumatology and Immunology, Duke University, Durham, NC, ¹⁰ITN, San Francisco, CA, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Damage related to active disease or its treatment is an important outcome measure in ANCA-associated vasculitis (AAV). The Vasculitis Damage Index (VDI), the principal…
Abstract Number: 878 • 2015 ACR/ARHP Annual Meeting
Significance of Interstitial Pneumonitis in Microscopic Polyangiitis
Kensuke Nakanishi and Mitsuyo Kinjo, Rheumatology, Okinawa Chubu Hospital, Uruma, Japan
Background/Purpose: Microscopic polyangiitis (MPA) is often associated with lung involvement, including alveolar hemorrhage and interstitial pneumonitis (IP). Clinical characteristics of IP in MPA have not…
Abstract Number: 1766 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinicopathologically- and Serologically-Based Classification Systems for ANCA-Associated Vasculitis
Sebastian Unizony¹, Eli M. Miloslavsky¹, Miguel Villarreal², Peter A. Merkel³, Paul Monach⁴, E. William St. Claire⁵, Cees Kallenberg⁶, David Ikle², Robert F. Spiera⁷, Nadia Tchao⁸, Deborah J. Phippard⁸, Linna Ding⁹, Carol A. Langford¹⁰, Philip Seo¹¹, Gary S. Hoffman¹², John H. Stone¹ and Ulrich Specks¹³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Rho, Chapel Hill, NC, ³University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology, Boston University, Boston, MA, ⁵Rheumatology, Duke University School of Medicine, Durham, NC, ⁶Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Immune Tolerance Network, Bethesda, MD, ⁹NIAID, Bethesda, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose Genome-wide association studies suggest that PR3-ANCA-positive ANCA-associated vasculitis (AAV) is genetically distinct from MPO-ANCA AAV. We evaluated patients enrolled in the RAVE trial according…
Abstract Number: 1765 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase-3
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: To correlate the clinical characteristics of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with myeloperoxidase (MPO)-ANCA and proteinase-3 (PR3)-ANCA, and to detect clinical characteristics of…
Abstract Number: 1783 • 2014 ACR/ARHP Annual Meeting
The Importance of Histopathological Classification of ANCA-Associated Glomerulonephritis in Renal Function and Renal Survival
Valeria Scaglioni¹, Marina Scolnik¹, Luis J. Catoggio¹, Carlos Federico Varela², Gustavo Greloni², Silvia Christiansen³ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose : Histological changes in renal biopsy are the gold standard for establishing the diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). In 2010 a…
Abstract Number: 1755 • 2014 ACR/ARHP Annual Meeting
Proteomic Analysis of ANCA Vasculitis Serum Reveals Broad Neutrophil Activation, Angiogenesis, and Selective Inflammatory Pathway Activation
Melissa Parker, David Gold, Koustubh Ranade and Ethan Grant, Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose ANCA vasculitis is characterized by the presence of autoantibodies directed against MPO, PR3 and other neutrophil proteins. Binding of these autoantibodies to activated neutrophils…
Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…
Abstract Number: 1764 • 2014 ACR/ARHP Annual Meeting
Clinical and Other Differences Observed Between Cocaine Induced and Non-Cocaine Induced Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis
Santhi Penmetsa¹, N. Suzanne Emil², Joshua Duchesne¹, Wilmer Sibbitt Jr.³, Arthur Bankhurst⁴ and Roderick Fields⁵, ¹Rheumatology, University of New Mexico Health sciences center, Albuquerque, NM, ²Rheumatology, Presbyterian Medical Group, Rio Rancho, NM, ³Rheumatology, University of New mexico health sciences center, Albuquerque, NM, ⁴Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ⁵Division of Rheumatology, University of New Mexico health Sciences center, Albuquerque, NM
Background/Purpose Objective: To compare various factors including clinical manifestations, laboratory data and mortality in between two groups of patients with anti-neutrophil cytoplasmic antibody (ANCA) positive…
Abstract Number: 804 • 2014 ACR/ARHP Annual Meeting
Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature
Alice Sy¹, Natasha Dehghan², Nader A. Khalidi³, Lillian Barra⁴, Simon Carette⁵, David Cuthbertson⁶, Gary S. Hoffman⁷, Curry L Koening⁸, Carol A. Langford⁹, Carol McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Philip Seo¹³, Ulrich Specks¹⁴, Steven R. Ytterberg¹⁵, Gert Van Assche¹⁶, Peter A. Merkel¹⁰ and Christian Pagnoux⁵, ¹Medicine Division, London, ON, Canada, ²Rheumatology Division, Vancouver, BC, Canada, ³Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, St. Joseph's Health Care, London, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶Department of Biostatistics, University of South Florida, Tampa, FL, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University, Boston, MA, ¹²Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Johns Hopkins Vasculitis Center, Rheumatology Division, Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Small case series suggested that vasculitis and inflammatory bowel disease (IBD; Crohn’s disease [CD] or ulcerative colitis [UC]) can co-occur more commonly than the…
Abstract Number: 2903 • 2014 ACR/ARHP Annual Meeting
Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)
Kimberly Morishita¹, Susanne Benseler², Rae S.M. Yeung³, Thomas Mason II⁴, Dawn Wahezi⁵, Kenneth N. Schikler⁶, Erica F. Lawson⁷, Susan Nielsen⁸, Sirirat Charuvanij⁹, Paul Dancey¹⁰, Susan Shenoi¹¹, Linda Wagner-Weiner¹², Angelyne Sarmiento¹, David A. Cabral¹³ and For the PedVas Initiative¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology - Department of Medicine, Mayo Clinic, Rochester, MN, ⁵Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁶Department of Pediatrics, Univ of Louisville Schl of Med, Louisville, KY, ⁷Pediatrics, University of California, San Francisco, San Francisco, CA, ⁸Pediatric rheumatology, Rigshospitalet, Copenhagen, Denmark, ⁹Pediatrics, Siriraj Hospital, Bangkok, Thailand, ¹⁰Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹¹Pediatric Rheumatology, Seattle Childrens Hospital, seattle, WA, ¹²Pediatric Rheumatology, University of Chicago Hospital, Chicago, IL, ¹³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Childhood AAV is rare and outcome studies are limited. The PedVas Study is an international initiative collecting clinical data (to A Registry of Childhood…
Abstract Number: 85 • 2014 ACR/ARHP Annual Meeting
Protective Association of HLA-DRB1*13:02 Against MPO-ANCA Positive ANCA-Associated Vasculitis in a Japanese Population
Naoyuki Tsuchiya¹, Narumi Hasebe¹, Ken-ei Sada², Shigeto Kobayashi³, Hidehiro Yamada⁴, Hiroshi Furukawa⁵, Kunihiro Yamagata⁶, Takayuki Sumida⁷, Nobuyuki Miyasaka⁸, Seiichi Matsuo⁹, Shigeto Tohma⁵, Shoichi Ozaki¹⁰, Hiroshi Hashimoto¹¹, Hirofumi Makino², Masayoshi Harigai¹² and Aya Kawasaki¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁶Department of Internal Medicine (Nephrology), Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁷Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁸Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁰Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹¹Juntendo University School of Medicine, Tokyo, Japan, ¹²Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose Epidemiology of antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV) is substantially different between European and Asian populations. In the Japanese population, the majority…
Abstract Number: 2278 • 2014 ACR/ARHP Annual Meeting
Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis
Amanda Schlefman¹, Maureen Leffler², AnneMarie C. Brescia³ and Carlos D. Rose⁴, ¹A.I. DuPont Hospital for Children, Wilmington, DE, ²Rheumatology, AI duPont Hospital for Children, Wilmington, DE, ³Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ⁴Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Ocular involvement, particularly orbital pseudotumor, has been reported as the initial manifestation of ANCA-associated vasculitis (AAV) in the adult population, predominantly in granulomatosis with…
Abstract Number: 2186 • 2014 ACR/ARHP Annual Meeting
Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Christian Lood and Grant C. Hughes, Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Illicit cocaine use is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of clinical manifestations. However, the mechanisms linking…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].